Entrada Therapeutics Inc (TRDA)
17.74
+0.14
(+0.82%)
USD |
NASDAQ |
Nov 04, 16:00
17.76
+0.01
(+0.06%)
After-Hours: 20:00
Entrada Therapeutics EPS Diluted (Quarterly): 1.55 for June 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.55 |
| March 31, 2024 | 0.68 |
| December 31, 2023 | -0.29 |
| September 30, 2023 | 1.02 |
| June 30, 2023 | -0.78 |
| March 31, 2023 | -0.21 |
| December 31, 2022 | -0.79 |
| September 30, 2022 | -0.80 |
| Date | Value |
|---|---|
| June 30, 2022 | -0.74 |
| March 31, 2022 | -0.69 |
| December 31, 2021 | -0.89 |
| September 30, 2021 | -0.5097 |
| June 30, 2021 | -0.4835 |
| March 31, 2021 | -0.4093 |
| December 31, 2020 | -0.4236 |
| September 30, 2020 | -0.3414 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.89
Minimum
Dec 2021
1.55
Maximum
Jun 2024
-0.2567
Average
-0.4536
Median
EPS Diluted (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 0.87 |
| Sarepta Therapeutics Inc | 0.07 |
| Catalyst Pharmaceuticals Inc | 0.33 |
| Vertex Pharmaceuticals Inc | -13.92 |
| Regenxbio Inc | -1.05 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 55.03M |
| Revenue (Quarterly) | 94.69M |
| Total Expenses (Quarterly) | 41.27M |
| Enterprise Value | 184.97M |
| Profit Margin (Quarterly) | 58.11% |
| Earnings Yield | 16.68% |
| Operating Earnings Yield | 15.22% |
| Normalized Earnings Yield | 16.68 |